Pacific Biosciences of California Inc (NAS:PACB)
$ 1.86 -0.07 (-3.63%) Market Cap: 568.03 Mil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 1.17 GF Score: 55/100

Pacific Biosciences of California Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 05:15PM GMT
Release Date Price: $28.16 (-1.09%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey everyone, good afternoon. Thanks for joining us at the Morgan Stanley Global Healthcare Conference today. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here. Delighted to have Pacific Biosciences join us this afternoon. And representing the company, we have Christian Henry, CEO; and Susan Kim, CFO. Welcome to you both.

Before we get into the Q&A, just had a quick safe harbor to rattle off. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales rep.

So with that, Christian, welcome, again. Clearly, just to set the stage, I mean, there's been a transformation underway at PacBio since you took the CEO seat about a year ago. You have the SoftBank deal. You have the Invitae collaboration. Since then you've purchased Omniome and Circulomics and strengthened the commercial team, of course. So as you look ahead to 2022, could you outline for us what you think is the next leg of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot